Richard W. Paul & Associates LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Richard W. Paul & Associates LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 21.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 39,454 shares of the biopharmaceutical company’s stock after buying an additional 7,100 shares during the quarter. Richard W. Paul & Associates LLC’s holdings in Pfizer were worth $956,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Carnegie Investment Counsel lifted its holdings in shares of Pfizer by 15.8% in the first quarter. Carnegie Investment Counsel now owns 55,326 shares of the biopharmaceutical company’s stock worth $1,277,000 after buying an additional 7,557 shares in the last quarter. Journey Strategic Wealth LLC grew its stake in Pfizer by 12.7% during the first quarter. Journey Strategic Wealth LLC now owns 28,555 shares of the biopharmaceutical company’s stock valued at $724,000 after acquiring an additional 3,210 shares in the last quarter. Finally, Brookwood Investment Group LLC bought a new stake in Pfizer during the 1st quarter worth approximately $227,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on PFE shares. Morgan Stanley cut their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Trading Up 2.5%

NYSE PFE opened at $25.02 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock’s 50-day simple moving average is $24.84 and its two-hundred day simple moving average is $24.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a market capitalization of $142.26 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.